At Lahjavida Bio, we’re developing a new class of small-molecule Dye-Drug Conjugates (DDCs) designed to concentrate potent cancer therapies in tumors while sparing healthy tissue. Our first-in-class platform aims to improve precision and tolerability by reducing the systemic toxicity that limits many current treatments.
Lahjavida Bio’s DDC platform combines advanced dye chemistry, innovative linker design, and deep oncology expertise to create therapies with the potential to achieve both strong anti-tumor activity and a more favorable safety profile.
Watch Video
The therapeutic candidates described on this website are investigational and are currently in preclinical development. They have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.
All forward-looking statements—including those regarding scientific progress, development timelines, potential indications, safety or efficacy expectations, regulatory pathways, market opportunities, financing plans, or strategic partnerships—are based on current assumptions and are subject to significant risks and uncertainties. Actual results may differ materially.
Nothing on this website constitutes medical advice, an offer to sell securities, or a solicitation of investment. Any references to potential clinical, commercial, or scientific outcomes are aspirational, dependent on future data, and not guarantees of performance.
Lahjavida Bio undertakes no obligation to update forward-looking statements or projections. Use of this information is at the reader’s discretion.
Invest in Precision Oncology